ASCO 2026 highlights—nongenetically driven non-small cell lung cancer
This short review summarizes recent therapeutic approaches in advanced non-small cell lung cancer lacking actionable genomic alterations presented at the 2026 American Society of Clinical Oncology annual meeting. Particular emphasis was placed on bispecific antibodies and antibody-drug conjugates and their potential...